Manager Process
Resume:
LEV Z. VILENCHIK, Ph. D, Dr. Sc.
** ******'s Forest Drive, Waltham, MA 02154,
Home: 781-***-****, Cell: 617-***-****
E-mail: ***.*********@*****.***
Summary
Scientist with extensive expertise in analytical and physical chemistry, instrumentation, physics, polymer science, biochemistry, chromatography, mass spectrometry, drug discovery and screening including determination of protein-ligand binding characteristics (HPLC, LC-MS, other detection systems, e.g. RI, UV, MALS, ELSD, Viscometer). Significant experience in characterization and purification of small molecules and macromolecules (including proteins and peptides), their interaction, phase transactions, association and complex formation. Experience with measuring size of microparticles and their size distribution.
Managing experience as a group leader.
Objective: Position in Analytical Development
Experience:
Merck & Co., Cambridge, MA; Senior Principal Scientist 11/2009-1/2011
Developed a novel method of "Enhanced Ligand Affinity Characterization by LC-MS" (ELAC) to support ALIS (Automatic Ligand Identification System) operations and protein production in Protein Science Group. ELAC enables the complete characterization of the protein-ligand binding, including proteins and ligands solubility, stability and activity, Kd determination, stoichiometry, site of the binding and its type (covalent, non-covalent, specific, non-specific).
Schering-Plough Res Inst, Cambridge;
Sr. Principal Scientist/Group Leader 2/2005-11/2009
Developed synthesis, transferred to ALIS and filed a patent for novel media for drug screening process (Media-27). Developed method for ligand libraries preparation for ALIS screening that improves significantly the ligand solubility in aqueous buffer and prevents precipitation-mediated ligand loss. Developed method for Kd determination for GPCR targets.
Proposed ALIS-based method for quantitative bioanalytical analysis (including metabolic stability) and pharmacokinetical studies.
Developed, used and transferred to ALIS a specific system for high quality column packing (all SEC columns used by ALIS were packed using this system).
Neogenesis Pharmaceutical, Cambridge;
Principal Scientist/Group Leader 2/1998-2/2005
Was part of a team that developed a foundation for a model of the advanced drug screening process, ALIS.
Designed a special media for this process (Media 1 & Media 2).
Participated in the development of advanced LC-MS method for preparative ligands isolation.
Developed a novel three-column method for determination of equilibrium and kinetic binding characteristics, (Kd, Kon & Koff) for any target-ligand complexes.
Altus Biologics, Cambridge, MA; Senior Consultant 12/1996-2/1998
Developed a novel media based on cross-linked protein crystals and elaborated chiral
chromatography using the media.
Massachusetts Institute of Technology, Cambridge, MA;
Visiting Scientist 9/1996-12/1996
While working in the Department of Chemistry, developed a general thermodynamic model for protein solubility in organic solvents.
PerSeptive Biosystems, Framingham, MA; Senior Consultant 12/1995-8/1996
Developed methods for purification and analysis of different biological substances. Characterized porous media for perfusion chromatography using Malvern devices (for measuring particle size) and pore size distribution in the particles with using mercury porosimetry and a specific method of "Chromatographic Porosimetry".
Focal Interventional Therapeutics, Lexington, MA; Senior Scientist 9/1993-12/1995
Polymer, gel and drug characterization by a variety of analytical methods e.g., chromatography, light scattering, mass spectrometry, infrared spectroscopy, viscometry. Studied micelle formation from the "focal gel"; determined micelle size using multi-angle Light Scattering (MALS).
Wyatt Technology Corporation, Santa Barbara, CA; Senior Consultant 6/1993-9/1993
Application of multi-angle light scattering (MALS) for macromolecular characterization
Monsanto Chemical Co., Indian Orchard, MA;
Sr. Scientist/Group Manager 1990-1993
Managed a group of 7 people in Physical and Analytical Science Center . Developed analytical methods for characterization of linear and branched macromolecules, oligomers, block and statistical copolymers. Established a correlation between product properties on the molecular level and final product performance. Developed algorithm for production of SEC media with linear calibration according to molecular mass.
Purdue University, Indianapolis, IN; Visiting Professor 1989 -1990
Taught courses for graduate students (Department of Chemistry: Courses): Physical Chemistry, Properties of Macromolecules in Solutions; High Performance Liquid Chromatography (HPLC), and Instrumental Analysis.
Institute of Macromolecular Compounds, Leningrad, USSR; Scientist, Senior Scientist,
then Principal Scientist 1974-1988
Developed a theory and methods for study of macromolecules in solution, their phase
transactions, interaction, association and complex formation. Developed a theory of
macromolecular chromatography and theory for chromatographic process optimization (see "Modern Liquid Chromatography of Macromolecules", Elsevier, 1984). Developed a variety of analytical methods using SEC, RPC, NPC, IEC, chiral LC and light scattering for separation, purification and characterization of proteins, small molecules, oligomers and polymers.
Education
Dr. Sc. Analytical/Macromolecular Chemistry Institute of Macromolecular Compounds 1985
Ph. D. Physical and Analytical Chemistry
Leningrad Polytechnic University
1974
M. S. Leningrad State University
1967
Patents and Publications
Over 100 publications in Soviet and international journals; holder of some number of patents in macromolecular science and chromatography.
Some recent publications:
1. AC-MS Methodology for Quantitative Analyses of Small Molecule-Protein Binding in Solution; Lev Z Vilenchik with co-authors, Analytical Biochemistry, 2011, 418(1),pp.10-18
2. Novel benzimidazole inhibitors bind to a unique site in the kinesin spindle protein motor domain; Z Vilenchik with co-authors, . Biochemistry. 2011 Sep 20;50 (37):7964-76 .
3 Fully Activated MEK1 exhibits compromised affinity for binding of allotter inhibitors U0126 and PD0325901; Lev Z Vilenchik with co-authors, Biochemistry, 2010, Sep 28;49(38),8350-8358.
4. An affinity selection–mass spectrometry method for the identification
of small molecule ligands from self-encoded combinatorial libraries; Lev Z Vilenchik with co-authors; International Journal of Mass Spectrometry 2004 vol. 238, no. 2, pp. 77-83.
5. . Determination of equilibrium and kinetic characteristics for ligand-protein binding by tandem of size-exclusion and reverse phase chromatography; Lev Vilenchik and Krishna Kalghatgi, 3-d International Symposium on Separations in BioSciences, Moscow, 2003, p. O-49.
6. Protein Crystals as Novel Microporous Materials; Lev Z Vilenchik with co-authors,
J. Am. Chem. Soc., 1998, 120 (18), pp 4290–4294.
7. New developments in liquid chromatographic analysis of branched polymers; Lev Vilenchik and Roger Ayotte, Journal of Applied Polymer Science, 1992,51,73-90.
8. Characterization of a single sample of an unknown polymer by size exclusion chromatography; Lev Z Vilenchik with co-authors, Journal of Polymer Science Part B: Polymer Physics, August 1991Volume 29, Issue 9, pages 1137–1140
9. Theoretical aspects of the chromatographic analysis of heterogeneous polymers; L.Z.Vilenchik, Journal of Chromatography, 1990, 511, 49-58.
10. "Method for Size Exclusion Chromatography", Lev Z Vilenchik with co-authors, United State Patent #5,190,658; March 1993,
Monographs:
1. "Chromatography of Polymers"(co-author B.G.Belenky) (Moscow, 1978);
2. "Modern Liquid Chromatography of Macromolecules"(co-author B.G.Belenky) (Elsevier, 1984).
3. Chapter: Method for studying micelle formation using Size Exclusion Chromatography, Light Scattering, and UV Spectroscopy, in the book: "Strategies in Size Exclusion Chromatography" (ACS, Washington, DC, 1996, pp 328-346)
Personal:
USA citizen, fluent in English and Russian (native)
References: Available upon request
Contact this candidate